GENERATION BIO CO
Generation Bio Co (GBIO) is a clinical‑stage biotechnology company focused on developing non‑viral gene delivery and durable expression therapies. With a market capitalisation around $43.17M, GBIO is a small‑cap, research‑intensive name where valuation is highly dependent on scientific progress and milestones. Investors should expect volatility driven by clinical data readouts, regulatory news and potential partnership announcements. The company appears to have limited revenue and relies on funding, which can lead to dilution if additional capital is needed. Key considerations include the strength of the delivery platform, trial results, IP position and cash runway. This profile is suitable only for investors comfortable with high-risk, high-uncertainty biotech equities; it is educational information and not personal advice. Outcomes can vary, and past events are not a reliable guide to future performance.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Generation Bio's stock, anticipating a potential increase in value.
Financial Health
Generation Bio is generating modest revenue and cash flow, with a stable book value per share.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring GBIO
Pioneers Of Safer Gene Therapies
Discover a carefully selected group of innovative companies developing alternatives to traditional viral vector gene therapies. These stocks represent biotechs working on potentially safer genetic medicine technologies like siRNA and antisense oligonucleotides, handpicked by professional analysts for their pioneering approaches.
Published: July 21, 2025
Explore BasketBiotech's IP Moat
This carefully selected group of stocks features biotech companies with powerful patent portfolios. These firms are at the forefront of medical innovation in areas like gene editing and mRNA technology, where intellectual property can create lasting competitive advantages and drive long-term growth.
Published: July 11, 2025
Explore BasketCell & Gene Therapy Logistics
This carefully curated collection features companies providing the essential infrastructure that makes advanced cell and gene therapies possible. Selected by expert analysts, these stocks represent the "picks and shovels" of the biotech revolution—giving you exposure to regenerative medicine's growth without the direct risks of clinical trials.
Published: June 17, 2025
Explore BasketAge-Reversal Biotech
Invest in pioneering companies that are redefining aging as a treatable condition. These carefully selected biotechs are developing groundbreaking therapies to extend healthy lifespans and potentially reverse cellular damage, creating an entirely new frontier in medicine.
Published: June 17, 2025
Explore BasketLottery Tickets
These visionary companies are betting it all on game-changing innovations that could revolutionize entire industries. Hand-selected by our analysts, each represents a high-risk, high-reward opportunity with potential for explosive growth if their breakthrough technologies succeed.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Milestones Drive Value
Clinical readouts, regulatory steps and partnerships can change sentiment quickly, though outcomes may be binary and cause volatility.
Platform Potential
Non‑viral delivery aims for durable expression and broader patient reach, but technical and regulatory hurdles remain and success is uncertain.
Small Cap Considerations
Market cap near $43M implies higher volatility and possible dilution; typically suited to investors with higher risk tolerance.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ARCELLX, INC.
Develops T-cell therapies for the treatment of cancer.
AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
